PharmAbcine

Notifications

Back

Notification settings

Back

Post notifications

Be notified when someone leaves a comment or a reply to your post or comment.

Updates and news

Stay ahead of important updates and news from the site.

Alarm
My account Sign out

Sign-in required.

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Olinvacimab
PMC-309
PMC-402
PMC-403

Recruiting Procedure
Careers Guide
Job Openings

Location
Inquiry
Partnership Request

한국어
English

About Us

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Pipeline

Olinvacimab
PMC-309
PMC-402
PMC-403

For Investors

For Media

Careers

Recruiting Procedure
Careers Guide
Job Openings

Contact

Location
Inquiry
Partnership Request

한국어
English

About Us

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Pipeline

Olinvacimab
PMC-309
PMC-402
PMC-403

For Investors

For Media

Careers

Recruiting Procedure
Careers Guide
Job Openings

Contact

Location
Inquiry
Partnership Request

한국어
English

한국어
English

Core Technology

For Media

Press Release PharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403

TitlePharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403Cat

18 Dec 2025 Views 834

Press Release PharmAbcine’s PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors

Title PharmAbcine’s PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in P

21 Aug 2025 Views 2745

News Article PharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025_THE BIO

TitlePharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025 CategoryNews

9 Jun 2025 Views 3410

Press Release PharmAbcine’s PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors

TitlePharmAbcine’s PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced

19 May 2025 Views 3735

Media Center

Subscribe to our website to get latest updates (email@exmaple.com)

Confirm

No
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
Title
Author
Time uploaded
Views
Likes

196
Press Release
Press Release PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024
PharmAbcine
23 May 2024
Views5082
0

195
Press Release
Press Release Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
PharmAbcine
23 Apr 2024
Views4932
0

194
Press Release
Press Release PharmAbcine Announces Japan Patent Registration for PMC-403
PharmAbcine
29 Feb 2024
Views4184
0

193
Press Release
Press Release PharmAbcine's PMC-403 Receives FDA Orphan Drug Designation for Idiopathic Systemic Capillary Leak Syndrome
PharmAbcine
20 Feb 2024
Views3702
0

192
Press Release
Press Release PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
PharmAbcine
24 Jan 2024
Views3961
0

191
Press Release
Press Release PharmAbcine’s Phase 1 Ophthalmology Program PMC-403 Selected by the KDDF for Government-initiated Drug Development Program
PharmAbcine
6 Dec 2023
Views3720
0

190
Press Release
Press Release PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome
PharmAbcine
23 Nov 2023
Views3306
0

189
Press Release
Press Release PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data
PharmAbcine
9 Nov 2023
Views3396
0

188
Press Release
Press Release PharmAbcine Receives HREC Approval in Australia for the Phase 1a/b Trial of Its Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
PharmAbcine
18 Sep 2023
Views3540
0

187
Press Release
Press Release PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
PharmAbcine
24 May 2023
Views4649
0

Previous
1
2
3
4
5
6
7
8
9
Next

About Us
Core Technology
Pipeline
- Olinvacimab
- PMC-309
- PMC-402
- PMC-403
For Investors
For Media
Careers
Contact

LinkedIn I Facebook I YouTube

- 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil,
  Yuseong-gu, Daejeon, 34047, Republic of Korea
- HQ +82-42-863-2017
- R&D Center +82-42-861-2017
- FAX +82-42-863-2080
COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.

2F, Research Building 2, 70,

Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea

HQ +82-42-863-2017

R&D Center +82-42-861-2017

Investor Relations +70-4294-6097

FAX +82-42-863-2080

COPYRIGHT BY PharmAbcine Inc.

ALL RIGHTS RESERVE